10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Survey of professional views on sharing interim results by the Data Safety Monitoring Board (DSMB): what to share, with whom and why

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Sharing interim results by the Data Safety Monitoring Board (DSMB) with non-DSMB members is an issue that can affect trial integrity. It is unclear what should be shared. This study assesses the views of professionals to understand what interim information should be shared at interim, with whom and why.

          Methods

          Conducted an online survey of members of the Society of Clinical Trials (SCT) and International Society of Clinical Biostatistics (ISCB) in 2015 asking their professional views on sharing interim results. Email was used to advertise the survey and a link in the email was provided to the online survey.

          Results

          Approximately 3136 (936 SCT members + 2200 ISCB members) members were invited. The response rate was 12% (371/3136). The majority reported the Interim Control Event Rate (IControlER) (149/237; 62.9% [95% CI, 56.7–69.0%]), Adaptive Conditional Power (ACP) (144/224; 64.3% [95% CI, 58.0%–70.6%]) and the Unconditional Conditional Power (UCP) (126/208; 60.6% [95% CI, 53.9–67.2%]) should not be shared with non-DSMB members. The majority reported that the Interim Combined Event Rate (ICombinedER) (168/262; 64.1% [95% CI, 58.0–69.9%]) should be shared with non-DSMB members particularly the steering committee (SC) because it does not unmask interim results and helps with monitoring trial progress, safety, and design assumptions.

          Conclusion

          The IControlER and ACP are unmasking of interim results and should not be shared. The UCP is a technical measure that is potentially misleading and also should not be shared. The ICombinedER is usually known by the SC and sponsor making it easy to determine group rates if the IControlER is known. Though most respondents thought the ICombinedER should be shared with the SC as it does not unmask relative effects between groups, we do not recommend sharing the ICombinedER as it is flawed measure that can have multiple interpretations possibly suggesting that one group is performing better, worse or the same as a comparator group, leading to guesses about how groups are doing relative to one another.

          Electronic supplementary material

          The online version of this article (10.1186/s13063-018-2655-y) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Monitoring of clinical trials: issues and recommendations.

          Interim analyses of randomized trials enable investigators to make more efficient use of limited research resources and to satisfy ethical requirements that a regimen be discontinued as soon as it has been established to have an inferior efficacy/toxicity profile. Unfortunately, the integrity and credibility of these trials can be compromised if inappropriate procedures are used in monitoring interim data. In this paper we discuss how group sequential designs provide useful guidelines that enable one to satisfy the valid objectives of interim monitoring while avoiding undesirable consequences, and we consider how flexible one can be in the way such designs are implemented. We also provide motivation for the role of data-monitoring committees in preserving study integrity and credibility in either government- or industry-sponsored trials. In our view, these committees should have multidisciplinary representation and membership limited to individuals free of apparent significant conflict of interest, and ideally should be the only individuals to whom the data analysis center provides interim results on relative efficacy of treatment regimens. Finally, we discuss some important practical issues such as estimation following group sequential testing, analysis of secondary outcomes after using a group sequential design applied to a primary outcome, early stopping of negative trials, and the role of administrative analyses.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees.

            This is a commissioned report by a writing committee formed by the Society for Clinical Trials. The committee was formed with the objectives of 1) reviewing data monitoring guidelines for confirmatory (phase III) trials published by the National Institutes of Health, US Food and Drug Administration, Veterans Administration, and the International Conference on Harmonisation and 2) proposing corresponding guidelines for exploratory clinical trials (ie, most phase I and phase II trials and others not requiring a fully independent data monitoring committee). These trials typically involve fewer subjects and are of shorter duration than phase III trials. Nevertheless there are safety concerns, especially because these are often the first human trials for a new intervention. Recommendations are given for appropriate elements of a data monitoring plan, decision criteria for institution of a data monitoring committee (DMC), and critical elements for a DMC to consider in exploratory trials. Review and approval of data monitoring plans are suggested to fall under Institutional Review Board purview. Forming a committee with all the characteristics of a traditional phase III trial monitoring committee may be warranted for a small fraction of exploratory trials. Such a panel could consist of both trial investigators and outside members. The paper concludes with examples of data and safety monitoring practice from the University of Wisconsin Comprehensive Cancer Center and the AIDS Clinical Trials Groups.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              When should data and safety monitoring committees share interim results in cardiovascular trials?

                Bookmark

                Author and article information

                Contributors
                borgdevj@mcmaster.ca
                mbuagblc@mcmaster.ca
                paulj@mcmaster.ca
                buckleyn@mcmaster.ca
                thabanl@mcmaster.ca
                Journal
                Trials
                Trials
                Trials
                BioMed Central (London )
                1745-6215
                21 May 2018
                21 May 2018
                2018
                : 19
                : 281
                Affiliations
                [1 ]ISNI 0000 0004 1936 8227, GRID grid.25073.33, Health Research Methods, Evidence and Impact, McMaster University, ; Hamilton, Canada
                [2 ]GRID grid.416449.a, Biostatistics Unit, St Joseph’s Healthcare, ; Hamilton, Canada
                [3 ]ISNI 0000 0004 1936 8227, GRID grid.25073.33, Department of Anesthesia, , McMaster University, ; Hamilton, Canada
                Article
                2655
                10.1186/s13063-018-2655-y
                5963112
                29784030
                856f5fda-18ac-4c7c-aa99-72b9ff04721a
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 1 August 2017
                : 19 April 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Medicine
                data safety monitoring board (dsmb),data monitoring committee (dmc),interim result sharing,survey

                Comments

                Comment on this article